CastleVax Competitors

Located in Rochester, NY, Vaccinex is a privately held, clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies, therapeutic vaccines and other biologic products to treat serious diseases with unmet needs, including cancer, multiple sclerosis, and other autoimmune diseases. We conduct discovery research in-house and in collaboration with world-class academic institutions and biotechnology companies, and have an experienced in-house drug development management team to advance our pre-clinical and clinical stage biopharmaceutical development programs. Our development team is led by seasoned industry veterans with both operational and executive level biopharmaceutical industry experience in therapeutic biologics research, manufacturing, quality assurance, quality control, toxicology, pharmacology, drug regulatory affairs, and clinical affairs. We are committed to innovation in the way we approach drug discovery and development. We are committed to identifying and advancing therapeutics that work in novel ways to address unmet medical needs. We are committed to successfully meeting the challenge of treating patients with safe and effective medicines. We are committed to the patients who may use our drugs, and to our shareholders, our employees, and our community – all stakeholders in our success.

EpiVax has been providing immunogenicity expertise for over 25 years, helping pharmaceutical and biotech teams generate the insights they need to make informed decisions across biologic and vaccine programs. Our work ensures the success of pipelines at every stage, supporting companies ranging from emerging startups to global industry leaders. We take a risk-based, fit-for-purpose approach to immunogenicity assessment, helping developers focus on what matters most during each phase. From early discovery through regulatory submission and beyond, we integrate computational analyses, experimental in vitro assays, and expert consulting to generate actionable data that informs downstream development and regulatory strategies, mitigates risk, preserves resources, and strengthens confidence in program decisions. Our goal is to equip developers with the tools and insights needed to successfully advance safer and more effective treatments worldwide. As EpiVax continues to expand our capabilities, partnerships, and team of scientists, we’re stepping into a healthier future for all.

Biomax Informatics is now LabVantage - Biomax! Please visit our new presence here on LinkedIn: https://www.linkedin.com/company/labvantage-biomax